Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).

Employees

1,271

Sector

Biotechnology & Medical Research

Calendar

02-18 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-12-12	193.65 $	-0.81%	248,264
25-12-11	195.24 $	+2.84%	2,282,839
25-12-10	189.85 $	-2.22%	2,484,801
25-12-09	194.17 $	-1.21%	2,347,467
25-12-08	196.55 $	-3.65%	3,501,651

Delayed Quote Nasdaq, December 12, 2025 at 10:37 am

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

195.24USD

Average target price

224.89USD

Spread / Average Target

+15.19%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 10:53:03 2025-12-12 EST			5-day change	1st Jan Change
194.04 ^USD	-0.61%		-5.19%	+180.14%

12-05	Insmed Insider Sold Shares Worth $2,199,915, According to a Recent SEC Filing	MT
12-04	Insmed reports inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE

Capitalization	41.64B 35.43B 33.08B 31.03B 57.38B 3,756B 62.47B 385B 150B 1,774B 156B 153B 6,465B	P/E ratio 2025 *	-31.7x	P/E ratio 2026 *	-56.7x
Enterprise value	41.19B 35.05B 32.72B 30.7B 56.76B 3,716B 61.8B 381B 148B 1,755B 155B 151B 6,395B	EV / Sales 2025 *	80.1x	EV / Sales 2026 *	33.5x
Free-Float	98.99%	Yield 2025 *	-	Yield 2026 *	-

12-05	Insmed Insider Sold Shares Worth $2,199,915, According to a Recent SEC Filing	MT
12-04	Insmed reports inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
12-04	Rothschild & Co Redburn Initiates Coverage on Insmed With Buy Rating, $263 Price Target	MT
12-03	Insmed Insider Sold Shares Worth $1,841,101, According to a Recent SEC Filing	MT
12-02	Insmed Incorporated Presents at Evercore 8th Annual Healthcare Conference, Dec-02-2025 11:15 AM
12-01	Mizuho Raises Price Target on Insmed to $256 From $196, Keeps Outperform Rating	MT
11-18	Insmed Says European Commission Approves Brinsupri for Treatment of Non-Cystic Fibrosis Bronchiectasis	MT
11-18	Insmed Incorporated Receives European Commission Approval For BRINSUPRI As First Treatment For Non-Cystic Fibrosis Bronchiectasis	CI
11-18	Insmed Incorporated Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 08:30 AM
11-05	Insmed Insider Sold Shares Worth $4,985,911, According to a Recent SEC Filing	MT
10-31	Insmed Shares Likely to Gain From Brinsupri Sales, Untapped Pipeline, UBS Says	MT
10-31	RBC Raises Price Target on Insmed to $215 From $139, Keeps Outperform Rating	MT
10-31	Big Tech's Haunted Bill

12-04	Rothschild & Co Redburn Initiates Coverage on Insmed With Buy Rating, $263 Price Target	MT
12-01	Mizuho Raises Price Target on Insmed to $256 From $196, Keeps Outperform Rating	MT
10-31	Insmed Shares Likely to Gain From Brinsupri Sales, Untapped Pipeline, UBS Says	MT
10-31	RBC Raises Price Target on Insmed to $215 From $139, Keeps Outperform Rating	MT
10-31	UBS Adjusts Insmed Price Target to $223 From $194, Maintains Buy Rating	MT

Insmed Incorporated Stock

Equities

INSM

US4576693075

Biotechnology & Medical Research

Valuation: Insmed Incorporated

Chart: Insmed Incorporated

Latest news: Insmed Incorporated

Last Transcript: Insmed Incorporated

Analysts' recommendations: Insmed Incorporated

Press Releases: Insmed Incorporated

News in other languages: Insmed Incorporated

Quotes and Performance

Course Extremes

Managers and Directors: Insmed Incorporated

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

12-04	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	PR
11-20	Insmed wins first EU approval for non-cystic fibrosis bronchiectasis treatment	AQ
11-19	Insmed Incorporated - European Commission Approves BRINSUPRI as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union	AQ
11-18	European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union	PR
11-13	Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good	PR

10-31	Wall Street : La facture qui hante la Big Tech
10-03	Wall Street : Au sommet, encore
10-02	L'idylle de Wall Street avec la faiblesse
09-03	Wall Street : Antitrust en recul, rendements en hausse
08-20	Wall Street : Le consommateur américain fatigue

1 day	-0.67%
1 week	-5.19%
Current month	-6.91%
1 month	-0.50%
3 months	+32.54%
6 months	+99.64%
Current year	+180.14%

1 week	189.59	206.69
1 month	187.55	212.75
Current year	60.4	212.75
1 year	60.4	212.75
3 years	16.04	212.75
5 years	16.04	212.75
10 years	9.02	212.75

Manager	Title	Age	Since
Will Lewis CEO	Chief Executive Officer	56	2012-09-09
Sara Bonstein DFI	Director of Finance/CFO	44	2020-01-30
Martina Flammer CTO	Chief Tech/Sci/R&D Officer	61	2019-12-18

Director	Title	Age	Since
Melvin Sharoky CHM	Chairman	74	2009-06-15
Will Lewis CHM	Chairman	56	2018-11-07
David McGirr BRD	Director/Board Member	70	2013-10-29

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
INSMED INCORPORATED	-0.61%	-5.19%	+168.44%	+898.50%	41.64B
ARGENX SE	-0.32%	-2.15%	+29.71%	+99.05%	54.44B
WUXI APPTEC CO., LTD.	+0.70%	+4.98%	+63.03%	+17.56%	39.35B
BIONTECH SE	-0.58%	-0.65%	-20.77%	-42.61%	23.08B
GENMAB A/S	-1.22%	-0.49%	+35.89%	-37.80%	19.82B
WUXI BIOLOGICS (CAYMAN) INC.	0.00%	+1.64%	+81.76%	-37.88%	17.76B
SUMMIT THERAPEUTICS INC.	-1.42%	-3.17%	-0.78%	+528.72%	13.87B
AKESO, INC.	+6.05%	+0.89%	+96.84%	+203.66%	13.9B
MADRIGAL PHARMACEUTICALS, INC.	+0.66%	-0.58%	+89.76%	+803.02%	12.98B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+5.03%	-2.32%	+131.09%	-	12.51B
Average	+0.84%	-2.44%	+67.49%	+270.25%	24.94B
Weighted average by Cap.	+0.34%	-2.28%	+67.92%	+260.41%

	2025 *	2026 *
Net sales	514M 437M 408M 383M 709M 46.38B 771M 4.76B 1.85B 21.91B 1.93B 1.89B 79.83B	1.22B 1.04B 971M 911M 1.68B 110B 1.83B 11.31B 4.39B 52.06B 4.58B 4.49B 190B
Net income	-1.22B -1.04B -968M -908M -1.68B -110B -1.83B -11.28B -4.38B -51.94B -4.57B -4.48B -189B	-730M -621M -580M -544M -1.01B -65.87B -1.1B -6.76B -2.63B -31.12B -2.74B -2.68B -113B
Net Debt	-447M -380M -355M -333M -616M -40.33B -671M -4.14B -1.61B -19.05B -1.68B -1.64B -69.42B	-650M -553M -516M -485M -896M -58.64B -975M -6.02B -2.34B -27.7B -2.44B -2.39B -101B